Compare HOS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOS | NVAX |
|---|---|---|
| Founded | 1997 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 1996 | 1996 |
| Metric | HOS | NVAX |
|---|---|---|
| Price | $6.86 | $11.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $13.00 | ★ $14.22 |
| AVG Volume (30 Days) | 2.3M | ★ 8.1M |
| Earning Date | 11-08-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ 0.06 | N/A |
| Revenue | $876,561,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $78.64 | N/A |
| Revenue Next Year | $45.63 | N/A |
| P/E Ratio | $111.67 | ★ N/A |
| Revenue Growth | 3.60 | ★ 64.69 |
| 52 Week Low | $6.57 | $6.20 |
| 52 Week High | $9.41 | $13.39 |
| Indicator | HOS | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 27.29 | 50.30 |
| Support Level | N/A | $7.93 |
| Resistance Level | $8.16 | $11.73 |
| Average True Range (ATR) | 0.35 | 1.13 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 21.81 | 28.62 |
Hornbeck Offshore Services Inc, through its subsidiaries, operates offshore supply vessels (OSVs), multi-purpose support vessels (MPSVs), and a shore-base facility. It provides marine transportation, logistics support, and related services to customers in the offshore oil and gas industry, in the U.S. Gulf Coast region, Latin America, and other international markets. The company also serves non-oilfield markets, including military support services, renewable energy projects, and other marine service activities. The majority of revenue is derived from the provision of vessel management services to external vessel owners and from providing shore-based port facility services.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.